HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Birol Yamak Tulga Ulus Ouz Tademir Kemal Bayazit Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Katirciolu, S. F. Articles by Bayazit, K. Search for Related Content PubMed Articles by Katirciolu, S. F. Articles by Bayazit, K.

Mitral Valve Replacement with Bioprosthesis in Age Group Fifty to Sixty-Five Years

Salih Fehmi Katirciolu, MD, Birol Yamak, MD, Tulga Ulus, MD, Levent Birinciolu, MD, Ahmet Sarita, MD, Ouz Tademir, MD, Kemal Bayazit, MD

Department of Cardiovascular Surgery Türkiye Yüksek htisas Hospital Ankara, Turkey

Salih Fehmi Katirciolu, MD Department of Cardiovascular Surgery Türkiye Yüksek htisas Hospital 06100 Sihhiye Ankara, Turkey Tel:90 312 310 3080 Fax:90 312 466 3202 Email:Ulus{at}escortnet.com

Between 1982 and 1990, 151 patients aged 50 to 65 years of age underwent isolated mitral valve replacement with a bioprosthesis. Overall hospital mortality was 10.6% (16/151). The total cumulative follow-up period was 527.6 patient-years with a mean of 4.34 ± 2.53 years and a range of 2 months to 10.9 years. During the follow-up period, 27 patients (5.11% per patient-year) developed bioprosthesis dysfunction of whom 26 were reoperated and one was treated medically, 4 patients had thromboembolic complications (0.75% per patient-year), one patient (0.18% per patient-year) had anticoagulant-related bleeding, and two patients (0.37% per patient-year) had a paravalvular leak (one was reoperated). Total valve-related complications were 6.44% per patient-year. Late mortality was 2.65% per patient-year (14/151). Ten-year actuarial survival was 78.5%. Freedom from bioprosthesis dysfunction was 56.6%, from thromboembolic complications 95.8%, and from all complications 49.6%. Our findings of a high rate of bioprosthesis dysfunction as well as a low rate of thromboembolic complications after mitral valve replacement with a bioprosthesis in older patients suggests that the use of bioprostheses should be limited.